(Q34182845)

31 July 2017

title

First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report (English)

1 reference

31 July 2017

1 reference

7

Jalid Sehouli

0 references

Gülten Oskay-Özçelik

4

object named as

Gülten Oskay-Özcelik

0 references

author name string

Klaus Pietzner

1

1 reference

31 July 2017

Michael Jäger

2

1 reference

31 July 2017

Alexandra Schoberth

3

1 reference

31 July 2017

Marc Kuhberg

5

1 reference

31 July 2017

Horst Lindhofer

6

1 reference

31 July 2017

publication date

5 May 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

1391-1396

1 reference

Malignant ascites: new concepts in pathophysiology, diagnosis, and management

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

Malignant ascites: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

Immunotherapy of malignant ascites with trifunctional antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9961-5

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21544631

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21544631

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21544631

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-011-9961-5

1 reference

Dimensions Publication ID

31 July 2017

1019670603

0 references

1 reference